

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2008 (12.09.2008)

PCT

(10) International Publication Number
WO 2008/108794 A2

(51) International Patent Classification:
G01N 33/50 (2006.01)

Payton's Way, Orlando, FL 32828 (US). **DRAKE, Donald**
[US/US]; 919 Golfview Street, Orlando, FL 32804 (US).

(21) International Application Number:
PCT/US2007/014272

(74) Agent: **ZSKA, Suzanne, E.**; Merchant & Gould P.C., P.O.
Box 2903, Minneapolis, MN 55402-0903 (US).

(22) International Filing Date: 19 June 2007 (19.06.2007)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11/471,514 21 June 2006 (21.06.2006) US

(71) Applicant (*for all designated States except US*): **VAXDE-SIGN CORPORATION** [US/US]; 2721 Discovery Drive, Suite 400, Orlando, FL 32826 (US).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SANCHEZ-SCHMITZ, Guzman** [MX/US]; 12073 Fountain Brook Blvd., Apt 1446, Orlando, FL 32825 (US). **HIGBEE, Russell** [US/US]; 9321 Buttonwood Street, Orlando, FL 32825 (US). **FAHLENKAMP, Heather** [US/US]; 1800 W. Granger, Broken Arrow, OK 74012 (US). **IRVINE, Darrell, J.** [US/US]; 124 Brooks Avenue, Arlington, MA 02474 (US). **WARREN, William, L.** [US/US]; 13632

Published:

— *without international search report and to be republished upon receipt of that report*

(54) Title: CONTROLLING DENDRITIC CELL MATURATION STATE IN THE LYMPHOID TISSUE EQUIVALENT OF AN ARTIFICIAL IMMUNE SYSTEM

(57) Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate *in vitro* cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates *in vitro* and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.



WO 2008/108794 A2

TITLE

Controlling Dendritic Cell Maturation State in the Lymphoid Tissue Equivalent of an
Artificial Immune System

5

CROSS REFERENCE TO RELATED CASES

This application is a continuation-in-part of U.S. Application Serial No.

11/375,128, filed on March 15, 2006, which is a continuation-in-part of U.S. Application

10 Serial No. 11/116,234, filed April 28, 2005, which claims the benefit of priority of U.S.

Provisional Application Serial No. 60/565,846, filed April 28, 2004, and U.S. Provisional
Application Serial No. 60/643,175, filed January 13, 2005. This application is also a

continuation-in-part of U.S. Application Serial No. 11/375,033, filed on March 15, 2006,

which is a continuation-in-part of U.S. Application Serial No. 11/116,234, filed April 28,

15 2005, which claims the benefit of priority of U.S. Provisional Application Serial No.

60/565,846, filed April 28, 2004, and U.S. Provisional Application Serial No.

60/643,175, filed January 13, 2005. This application also claims the benefit of priority of

U.S. Provisional Application Serial No. 60/752,034, filed December 28, 2005. This

application further claims the benefit of priority of International Application No.

20 PCT/US2005/014444, filed April 28, 2005. Each of these applications is hereby

incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention is directed to a method for constructing an integrated artificial human tissue construct system and, in particular, construction of an integrated human immune system for *in vitro* testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics, and other chemicals. The artificial immune system of the present invention is useful for assessing the interaction of substances with the immune system, and thus can be used to accelerate and improve the accuracy and predictability of, for example, vaccine, drug, biologic, immunotherapy, cosmetic, and chemical development.

Background of the Technology

Despite the advent and promise of recent technologies, including combinatorial chemistry, high-throughput screening, genomics, and proteomics, the number of new drugs and vaccines reaching the market has not increased. In fact, the attrition rate within drug discovery programs exceeds 90%.

The introduction of these new (and expensive) technologies has not reduced the lost opportunity costs associated with immunotherapy development; rather, these costs have increased. It is now estimated that almost \$1 billion is required to bring a new drug to the market.

The development and biological testing of human vaccines has traditionally relied on small animal models (*e.g.*, mouse and rabbit models) and then non-human primate models. However, such small animal models are expensive and non-human primate

models are both expensive and precious. Furthermore, there are many issues regarding the value of such animal studies in predicting outcomes in human studies.

A major problem remains the translation from test systems (animal or 2-dimensional (2D) cell culture) to human immunology. Successful transfer between traditional testing systems and human biology requires an intricate understanding of disease pathogenesis and immunological responses at all levels.

The body's distributed immune system can be roughly divided into four distinct compartments: tissues and blood, mucosal tissues, body cavities, and skin. Because of ease of study, most is known about the tissue and blood compartment and its lymphoid tissues, the spleen and lymph nodes.

The largest compartment is the MALT (mucosa-associated lymphoid tissue). Mucosal surfaces serve a wide range of functions, including exchange of gases (lungs), nutrient transport (digestive tract), sensory surfaces (nose, mouth, throat), and reproductive signals.

Mucosal immunity is important for several reasons. First, the vast majority of human pathogens, including many of the leading infectious disease killers, initiate infections at mucosal surfaces, the largest routes of entry into the body. Additionally, stimulation of a mucosal immune response can result in production of protective B and T cells in both mucosal and systemic environments, so that infections are stopped or significantly hindered before they enter the rest of body. Significantly, bioterrorism relies on entry of agents through mucosal surfaces, where pathogens or toxins are primarily encountered, not as injections.

Because of its large surface area and exposure to the outside world, the mucosal system is also more vulnerable to infection than other body components (Newberry & Lorenz (2005) *Immunol Rev* 206, 6-21). As an example, the digestive tract has roughly 10^{14} commensal organisms and frequently encounters pathogens. Furthermore, an additional challenge for the gut-associated lymphoid system is that typical food antigens should be tolerated while pathogenic antigens should induce vigorous immune responses. A hallmark of the mucosal immune system is the production of secretory immunoglobulin A (IgA). MALT plasma cells secrete primarily dimeric IgA in an IgA₁:IgA₂ ratio of 3:2, whereas IgA secreted in the tissue and blood compartment is primarily monomeric IgA in an IgA₁:IgA₂ ratio of 4:1. IgA₂ is more resistant to proteolysis by pathogens than IgA₁ (*see, e.g.*, <http://microvet.arizona.edu/Courses/MIC419/Tutorials/bigpicture.html>).

The mammalian immune system uses two general adaptive mechanisms to protect the body against environmental pathogens. When a pathogen-derived molecule is encountered, the immune response becomes activated to ensure protection against that pathogenic organism.

The first immune system mechanism is the non-specific (or innate) inflammatory response. The innate immune system appears to recognize specific molecules that are present on pathogens but not on the body itself.

The second immune system mechanism is the specific or acquired (or adaptive) immune response. Innate responses are fundamentally the same for each injury or infection; in contrast, acquired responses are custom-tailored to the pathogen in question. The acquired immune system evolves a specific immunoglobulin (antibody) response to

many different molecules present in the pathogen, called antigens. In addition, a large repertoire of T cell receptors (TCR) is sampled for their ability to bind processed forms of the antigens bound to major histocompatibility complex (MHC, also known as human leukocyte antigen, HLA) class I and II proteins on the surface of antigen-presenting cells (APCs), such as dendritic cells (DCs).

The immune system recognizes and responds to structural differences between self and non-self proteins. Proteins that the immune system recognizes as non-self are referred to as antigens. Pathogens typically express large numbers of complex antigens.

Acquired immunity is mediated by specialized immune cells called B and T lymphocytes (or simply B and T cells). Acquired immunity has specific memory for antigenic structures; repeated exposure to the same antigen increases the response, which increases the level of induced protection against that particular pathogen.

B cells produce and mediate their functions through the actions of antibodies. B cell-dependent immune responses are referred to as "humoral immunity," because antibodies are found in body fluids.

T cell-dependent immune responses are referred to as "cell-mediated immunity," because effector activities are mediated directly by the local actions of effector T cells. The local actions of effector T cells are amplified through synergistic interactions between T cells and secondary effector cells, such as activated macrophages. The result is that the pathogen is killed and prevented from causing diseases.

The functional element of a mammalian lymph node is the follicle, which develops a germinal center (GC) when stimulated by an antigen. The GC is an active area within a lymph node, where important interactions occur in the development of an

effective humoral immune response. Upon antigen stimulation, follicles are replicated and an active human lymph node may have dozens of active follicles, with functioning GCs. Interactions between B cells, T cells, and FDCs take place in GCs.

Various studies of GCs *in vivo* indicate that the many important events occur there, including immunoglobulin (Ig) class switching, rapid B cell proliferation (GC dark zone), production of B memory cells, accumulation of select populations of antigen-specific T cells and B cells, hypermutation, selection of somatically mutated B cells with high affinity receptors, apoptosis of low affinity B cells, affinity maturation, induction of secondary antibody responses, and regulation of serum immunoglobulin G (IgG) with high affinity antibodies. Similarly, data from *in vitro* GC models indicate that FDCs are involved in stimulating B cell proliferation with mitogens and it can also be demonstrated with antigen (Ag), promoting production of antibodies including recall antibody responses, producing chemokines that attract B cells and certain populations of T cells, and blocking apoptosis of B cells.

Similar to pathogens, vaccines function by initiating an innate immune response at the vaccination site and activating antigen-specific T and B cells that can give rise to long term memory cells in secondary lymphoid tissues. The precise interactions of the vaccine with cells at the vaccination site and with T and B cells of the lymphoid tissues are important to the ultimate success of the vaccine.

Almost all vaccines to infectious organisms were and continue to be developed through the classical approach of generating an attenuated or inactivated pathogen as the vaccine itself. This approach, however, fails to take advantage of the recent explosion in our mechanistic understanding of immunity. Rather, it remains an empirical approach

that consists of making variants of the pathogen and testing them for efficacy in non-human animal models.

Given worldwide health problems caused by known and emerging infectious agents and even potential biological warfare pathogens, it is time for a fresh approach to understanding disease pathogenesis, the development and rapid testing of vaccines, and insights gathered from such work. Advances in the design, creation and testing of more sophisticated vaccines have been stalled for several reasons. First, only a small number of vaccines can be tested in humans, because, understandably, there is little societal tolerance for harmful side effects in healthy people, especially children, exposed to experimental vaccines. With the exception of cancer vaccine trials, this greatly limits the innovation that can be allowed in the real world of human clinical trials. Second, it remains challenging to predict which epitopes are optimal for induction of immunodominant CD4 and CD8 T cell responses and neutralizing B cell responses. Third, small animal testing, followed by primate trials, has been the mainstay of vaccine development; such approaches are limited by intrinsic differences between human and non-human species, and ethical and cost considerations that restrict the use of non-human primates. Consequently, there has been a slow translation of basic knowledge to the clinic, but equally important, a slow advance in the understanding of human immunity *in vivo*.

The artificial immune system (AIS) of the present invention can be used to address the inability to test many novel vaccines in human trials by instead using human tissues and cells *in vitro*. The AIS enables rapid vaccine assessment in an *in vitro* model

of human immunity. The AIS provides an additional model for testing vaccines in addition to the currently used animal models.

Attempts have been made in modulating the immune system. See, for example, U.S. Patent No. 6,835,550 B1, U.S. Patent No. 5,008,116, WO 2004/101773 A1, Suematsu *et al.* (*Nat Biotechnol*, 22, 1539-1545, (2004)), and U.S. Patent Application No. 2003/0109042.

Nevertheless, none of these publications describe or suggest an artificial (*ex-vivo*) human cell-based, immune-responsive system comprising a vaccination site (VS) and a lymphoid tissue equivalent (LTE). The present invention comprises such a system and its use in assessing the interaction of substances with the immune system.

SUMMARY OF THE INVENTION

The present invention provides an artificial immune system for assessing potential vaccine agents without administration to animal subjects. The artificial immune system comprises a 3D matrix comprised of lymphoid tissue (a lymphoid tissue equivalent) and populations of B cells and/or T cells distributed within the 3D matrix. Also distributed within the 3D matrix are dendritic cells.

The present invention also provides a means by which the state of maturation of the dendritic cells within the artificial immune system can be controlled.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. The state of the DCs can dictate naïve T cell migration behavior. DCs prepared using human serum (HS DCs) or fetal bovine serum (FBS DCs) were introduced into collagen gel containing autologous, negatively selected T cells. Initially,

T cells were uniformly distributed throughout the gel. However, by day 12, the distribution patterns were distinct. HS DCs caused T cells to distribute preferentially towards the top of the collagen, while FBS DCs induced migration to a lesser degree.

5 Figure 2. DCs prepared using human serum (HS DCs) or fetal bovine serum (FBS DCs) that had more of an immature or mature phenotype, respectively, were introduced into collagen gel containing autologous, negatively selected T cells. When tetanus toxoid-pulsed HS DCs or FBS DCs were introduced to the T cells, T cell proliferation was greater with FBS DCs than with HS DCs. Thus, the range of DC maturity states affects T
10 cell activation and proliferation.

Figure 3. OT-II reporter T cell responses were robustly detected at frequencies of about 1 antigen-specific cell per 100 T cells, and were still detectable at frequencies of about 1 antigen-specific cell per 10,000 T cells.

15 Wild-type (C57Bl/6) or OT-II ovalbumin (ova)-specific CD4⁺ T cells were mixed with mature ova-pulsed DCs (T:DC ratio ~10:1) in 96-well co-cultures. Proliferation and cytokine production were assayed after 3.5 days. The ratio of ova-specific OT-II T cells to wild-type cells was varied as shown.

(A) CFSE dilution flow cytometry analysis. Undivided T cells have a
20 fluorescence of ~103 units. Nearly all of the antigen-specific OT-II cells have divided multiple times in all cultures.

(B) IL-2 production detected in co-cultures in 96-well round-bottom plates or round-bottom plates with collagen gels.

Figure 4. Use of chemokine CCL21 to enhance the expansion of rare T cells *in vitro*.

CCL21 chemokine enhances the expansion/survival of antigen-specific T cells in co-cultures, modeling rare, specific T cell-DC encounters.

5

Figure 5. ECM production by BLS4 lymph node stromal cells. Antibody ER-TR7 was used to detect an ECM protein produced by lymph node stromal cells; it is known to colocalize with fibronectin in intact lymph nodes.

Figure 6. Lymphocyte survival *in vitro* is enhanced by co-culture with BLS4 lymph node
10 stromal cells. The graph shows number of live cells in control cultures (splenocytes alone) or splenocytes cultured on BLS4 monolayers over 11 days. Adding BLS4 cells resulted in ~4-fold more surviving splenocytes after 11 days.

Figure 7. The ratio of immature to mature dendritic cells present in T-DC co-cultures
15 impacts T cell proliferation and T cell survival.

Figure 8. BLS4 stromal cells form reticular networks in protein-conjugated inverse opal scaffolds.

(A) and (B) Stromal cells observed immediately after injection into scaffolds (a few cells
20 are highlighted by false-color overlays). Note the initially rounded morphology.

(C) and (D): After 24 hrs, BLS4 cells have attached to the scaffold and formed numerous intercellular connections stretching over and across pores of the scaffold. Shown are

fluorescence micrographs taken through midplanes of two regions of scaffold layers (red = stromal cell f-actin, blue = cell nuclei, green = protein-conjugated scaffold surfaces).

Figure 9. Immature population of reverse-transmigrated DCs from the vaccination site membrane (VSM) or the vaccination site cushion (VSC) is shown as CD83⁺ with few HLA-DR⁺ and CCR7⁺ observed. CD14 is slightly decreased in VSM compared to VSC. These are for phenotypes before maturation signals are provided (*e.g.*, TNF α).

Figure 10. After maturation with *Candida albicans*/tetanus toxoid antigens and TNF α , there was an increase in the number of cells that are high in CD14⁺ and HLA-DR. Additionally, some of these cells are expressing more CD83⁺/HLA-DR⁺/CCR7⁺ after antigen priming.

DETAILED DESCRIPTION OF THE INVENTION

The present invention concerns the development of accurate, predictive *in vitro* models to accelerate vaccine testing, allow collection of more informative data that will aid in redesigning and optimizing vaccine formulations before animal or clinical trials, and raise the probability that a vaccine candidate will be successful in human trials. More specifically, the present invention comprises controlling the maturation state of the dendritic cells (DCs) in the lymphoid tissue equivalent (LTE, artificial lymph node) of the artificial immune system (AIS), because the state of DC maturation appears to impact their behavior there.

Tissue engineering involves the development of synthetic or natural materials or devices that are capable of specific interactions with cells and tissues. The constructs combine these materials with living cells to yield functional tissue equivalents. Tissue engineering involves a number of different disciplines, such as biomaterial engineering, drug delivery, recombinant DNA techniques, biodegradable polymers, bioreactors, stem cell isolation, cell encapsulation and immobilization, and the production of 2D and 3D scaffolds for cells. Porous biodegradable biomaterial scaffolds are required for the 3D growth of cells to form the tissue engineering constructs. There are several techniques to obtain porosity for the scaffolds, including fiber bonding, solvent casting/particulate leaching, gas foaming/particulate leaching, and liquid-liquid phase separation. These produce large, interconnected pores to facilitate cell seeding and migration. As used herein, the terms "tissue-engineered construct" or "engineered tissue construct" ("ETC") include any combination of naturally derived or synthetically grown tissue or cells, along with a natural or synthetic scaffold that provides structural integrity to the construct.

It is known that 3D biology is important to induce proper functionality of immunological ETCs (*see, e.g.,* Edelman & Keefer, *Exp. Neurol.* **192**, 1-6 (2005)). A principal approach to studying cellular processes is to culture cells *in vitro*. Historically, this has involved plating cells on plastic or glass supports. Cells grown on solid or filter support are referred as two-dimensional (2D) cultures. Such 2D cultures on porous supports have been extremely useful for studying many aspects of biology. However, much more *in vivo*-like conditions can now be realized in 3D cultures. For example, many epithelial cells, both primary cultures and established lines, form complex epithelial structures when grown in 3D ECM.

Recently, in model *in vitro* lymph nodes, it has been shown that 3D interstitial tissue matrix facilitates not only T cell migration toward an APC, but also supports motility upon cell-cell interaction. A 3D collagen matrix environment, because of its spatial architecture, provides traction for lymphocyte crawling, mimicking some structural features of the lymph node cortex. This provides experimental justification for the importance of a 3D environment in the constructs that comprise the *in vitro* immune system.

The artificial immune system (AIS) of the present invention comprises a three-dimensional matrix comprised of lymphoid tissue. The matrix comprises a material selected from gelatin, collagen, synthetic ECM materials, PLGA, PGA, natural ECM materials, chitosan, protosan, and mixtures thereof. Distributed within the matrix comprising the lymphoid tissues are populations of at least one of B cells or T cells. Dendritic cells (mature and/or immature) are also distributed within the matrix.

Immature DCs (iDCs) and macrophages in the collagen cushion with naïve T cells tend to segregate the T cells into “zones” or clusters. An explanation may be that local chemokines and/or cytokines (such as CCL-21 and CXCL13) released from these APCs tend to act like “chemorepellants,” helping to organize the T/B cell zones in a 3D matrix similar to what is seen in lymph nodes *in vivo*.

Mature DCs in the collagen cushion release cytokines and/or chemokines (such as CCL-21 and CXCL13) and activate naïve T cells to proliferate and secrete cytokines. Thus, the state of APC differentiation in the model lymph node appears to affect the lymph node architecture and activation of lymphocytes.

The present invention comprises methods to modulate the state of antigen-presenting cells (APCs), including dendritic cells (DCs). More specifically, the present invention includes methods of modulating the state of APCs (*e.g.*, DCs) in the artificial immune system (AIS). The AIS of the present invention supports *in situ* priming of both
5 naïve T and B cells and subsequent interactions between activated antigen-specific helper T cells and B cells to promote B cell expansion, antibody class switching, and somatic hypermutation. Thus, the maturation state of the dendritic cells in the AIS of the present invention can be controlled, for example, by the choice of culture medium, by the choice of serum added to the culture media (Figs. 1,2), by the addition of cytokines and/or
10 chemokines added to the culture media (Fig. 4), or by the use of cells from a vaccination site.

The present invention comprises co-culture conditions to mimic the expansion of antigen-specific lymphocyte populations observed *in vivo*. It is a challenge to mimic the robust expansion of antigen specific T cells from their rare initial population to the
15 significant numbers present during the peak of *in vivo* immune responses. Such expansion can be dramatic *in vivo*; for example, in experimental lymphocytic choriomeningitis virus infection in mice, 100-200 naïve T cells specific for one antigen transiently expand to $\sim 10^7$ effector T cells, an expansion of about 50,000-fold (Blattman *et al.* (2002) *J Exp Med* 195, 657-664).

20 Furthermore, this is more rigorous than simply expanding T cells to a detectable population that could be correlated with a particular antigenic stimulation.

It requires that the cells, in fact, expand to a population size comparable to that observed *in vivo* to provide physiologic help for CTL and B cell priming.

The present invention comprises strategies comprising varying the cellular composition and presence of cytokines and/or chemokines in *in vitro* T cell cultures to better mimic the *in vivo* environment. These strategies enhance the expansion and survival of T cells primed under conditions of rare antigen-specific T cell-dendritic cell encounters.

In embodiments of the present invention, the cells are grown in dense co-cultures prepared in 96-well culture plates, to facilitate automation and rapid assessment of outcomes. Embodiments of the present invention include strategies to magnify the numbers of T cells expanded in single-step *in vitro* cultures. The strategies described can be implemented in a range of LTE formats, including inverse opal scaffolds, collagen matrices, and traditional well-format plate cultures.

The practice of the present invention will employ, unless otherwise indicated, conventional methods of immunology, histology, microbiology, cell and tissue culture, and molecular biology within the ordinary skill of the art. Such techniques are explained fully in the literature. All publications, patents, and patent applications cited herein are incorporated by reference in their entirety.

Examples

Example 1.

Detection limits with antigen-specific reporter cells. We developed a system to track rare antigen-specific T cells mixed with dilute antigen-presenting dendritic cells (DCs), as a means to define culture conditions for T cell priming *in vitro*. We used a murine transgenic CD4⁺ T cell (OT-II, which recognizes peptides from ovalbumin (ova))

for this purpose, to identify general culture conditions that can be applied to both the mouse and human systems. In this example, to mimic the rare occurrence of antigen-specific T cells, these 'reporter' cells were mixed with varying ratios of wild-type C57BL/6 CD4⁺ T cells, and bone marrow-derived dendritic cells. Cultures were prepared
5 with a fixed ratio of T cells to DCs of ~10:1, approximately matching the ratio of these cells in lymph nodes *in vivo*. An advantage of this system is that it allows quantitative labeling, isolating, and identifying antigen-specific cells in these cultures at all times, which is simply not possible *in vivo*.

We tested whether we could detect antigen-specific T cell priming at T cell

10 dilutions approaching the *in vivo* frequency of mouse and human naïve T cells.

OT-II ova-specific T cells were labeled with the fluorescent dye CFSE (used to track cell proliferation; each time a cell divides, its fluorescence is halved). OT-II T cells, wild-type T cells, and ova-pulsed mature DCs were mixed and cultured for 3.5 days.

As shown in Figure 3A, when OT-II T cells make up 10% of the T cells in the co-
15 culture (red curve), numerous rounds of cell division were detected, as indicated by the multi-peaked histogram. Undivided cells in this experiment had a fluorescence of ~103 units; thus nearly all the antigen-specific cells have divided several times.

As shown in the other curves, significant numbers of OT-II T cells that had proliferated were still detected when they made up only about 1% of the T cell
20 population, and further, detectable OT-II cells were found even when their frequency was only ~1 in 10,000 among the T cells initially added to the culture. Measurement of IL-2 production (Fig. 3B) and interferon- γ (IFN- γ) production (data not shown) showed a dose-dependent response that decayed as the number of OT-II cells present declined.

Thus, this system allows the mimicking of rare antigen-specific T cell encounters, even with precursor T cell frequencies similar to the rarity of natural naïve T cells *in vivo*.

Example 2.

5 When we compared T cell priming in dense 96-well cultures ($\sim 2 \times 10^5$ to $\sim 5 \times 10^5$ cells per well) to priming in collagen gels also prepared in 96-well plates, IL-2 production was about 50% of the level seen in the no-matrix case. This result is consistent with published data on T cell priming in collagen (Gunzer *et al.* (2000) *Immunity* 13, 323-332) and may reflect slower migration of T cells through the matrix in
10 their search for antigen-bearing DCs, relative to the cells-only aggregates formed in no-matrix cultures.

Example 3.

 In another embodiment of the present invention, the strategy to enhance
15 expansion of rare T cells *in vitro* comprises T cell-dendritic cell co-cultures, comprising a mixture of immature and mature DCs, to enhance the proliferation and survival of antigen-specific T cells. Immature DCs also aid in zone formation typical of *in vivo* lymph nodes (*see* Fig. 1). The collagen matrix model has enabled us to show basic results that suggest the maturation state of the DC may impact its behavior in the lymph node.
20 Immature DCs/macrophages in the collagen cushion with naïve T cells tend to segregate the T cells into “zones” or clusters. One possible explanation is the local chemokines released from these APCs tend to act like “chemorepellants” helping to organize the T/B cell zones in a 3D matrix similar to that found in the lymph node. Mature DCs in the

collagen cushion with naïve T cells activate these T cells to proliferate and secrete cytokines. Thus, the state of APC differentiation in the lymph node appears to assist in the formation of the lymph node architecture, or activation of lymphocytes.

5

Example 4.

Phenotypic and functional characterization of RT-DCs

10

To examine the determination of functional capacity and phenotypic characteristics of the vaccination site experiments were conducted to examine markers of DC differentiation and maturation. The phenotypic markers used to characterize cells related to the VS were the macrophage profile (CD68, CD206, CD36, CD205, CD209), DC profile (CD83, CD1a, CD205, CD207, CD208, CD209), maturation status profile (HLA-DR, CD40, CD80, CD86 CD16, CD32, CD64), chemokine receptor profile (CCR7, CCR2, CXCR4, CXCR5, CCR6), lineage profile (CD56, CD3, CD19, CD14, CD31, CD144) and survival markers such as annexin V or 7AAD. Reverse transmigration DCs (RT-DCs) were generated from the vaccination site collagen membrane and collagen cushion modules, presented with antigens (*Candida albicans*, tetanus toxoid combination, KLH), and driven to maturity with TNF α (Figs. 9, 10)

15

20

Example 5

Creation of lymph node-like stromal cell networks in the LTE and their impact on lymphocyte function. ECM production by BLS4 cells: Creation of 3D reticular structures by lymph node stromal cells cultured in 3D inverse opal LTE scaffolds

25

In addition to secreting factors that support lymphocyte survival and/or priming, lymph node stromal cells likely assist in providing the physical network in 3D cultures to support T cell and DC motility and subsequent interactions (Fig. 6).

When BLS4 (murine) stromal cells are placed in standard 2D culture plates, they
5 spread to form confluent layers typical of fibroblasts (Fig. 8) However, when BLS4 cells were injected into fibronectin/laminin-conjugated inverse opal LTE hydrogel scaffolds, their behavior and morphology were entirely different. Immediately after injection, the cells were rounded and situated within the void spaces of the scaffold (Fig. 8). Within
1 hr, we observed the cells attaching, spreading, and forming numerous intercellular
10 connections spanning multiple pores of the scaffold in all three dimensions. After 24 hrs, cells in scaffolds were fixed and stained with fluorescent markers for f-actin and cell nuclei to visualize the cells in 3D.

As can be seen in Figures 5 and 8, extensive cell-cell 3D interconnections similar to the 3D web-like nature of the natural stromal network in lymph nodes were evident.

15 In an experiment where stromal cells, lymphocytes, and dendritic cells were 're-aggregated' in culture without scaffolds to guide the stromal cell assembly, we observed lymphocytes with highly extended lamellipodia in fixed samples, suggesting that co-culture with stromal cells strongly influences lymphocyte attachment and polarization.

20 Example 6

OT-II and wild-type T cells (at a ~1:10 ratio) were mixed with DCs (total T:DC ratio ~10:1) in 96-well plate co-cultures and the ratio of immature to mature ova protein-pulsed DCs was varied. OT-II T cell proliferation was tracked by CFSE dilution.

Surprisingly, significantly greater T cell proliferation/survival was found when the ratio of immature to mature DCs was ~1:1, with fewer DCs initially bearing antigen than in the ~1:10 iDC:mDC case (Fig. 7).

- 5 The above description and examples are for the purpose of teaching the person of ordinary skill in the art how to practice the present invention, and it is not intended to detail all those obvious modifications and variations of it that will become apparent to the skilled worker upon reading the description. It is intended, however, that all such obvious modifications and variations be included within the scope of the present
- 10 invention, which is defined by the following claims. The claims are intended to cover the claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates the contrary.

WHAT IS CLAIMED IS:

1. An artificial immune system to permit the assessment of potential vaccine agents without administration to animal subjects, comprising:

a three-dimensional matrix comprised of lymphoid tissue;

5 a population of at least one of B cells or T cells distributed in said matrix; and dendritic cells distributed in said matrix.

2. The artificial immune system of claim 1, wherein said system comprises B cells and T cells distributed in said matrix, and said dendritic cells comprise both mature and
10 immature dendritic cells.

3. The artificial immune system of claim 1, wherein said matrix is in the form of an inverse opal scaffold, a collagen matrix, or a plate culture.

15 4. The artificial immune system of claim 1, wherein said matrix comprises a material selected from gelatin, collagen, synthetic ECM materials, PLGA, PGA, natural ECM materials, chitosan, protosan, and mixtures thereof.

5. The artificial immune system of claim 1, wherein said matrix comprises gelatin.
20

6. The artificial immune system of claim 1, wherein said matrix comprises synthetic ECM materials.

7. The artificial immune system of claim 1, wherein said matrix comprises PLGA.

8. The artificial immune system of claim 1, wherein said matrix comprises PGA.

5 9. The artificial immune system of claim 1, wherein said matrix comprises natural ECM materials.

10. The artificial immune system of claim 1, wherein said matrix comprises chitosan.

10 11. The artificial immune system of claim 1, wherein said matrix comprises protosan.

12. The artificial immune system of claim 1, wherein the ratio of mature to immature dendritic cells is adjusted so as to control the segregation and activation of the T cells and/or B cells.

15

13. The artificial immune system of claim 12, wherein the segregation of T cells is controlled by release of cytokines and/or chemokines by the immature dendritic cells.

14. The artificial immune system of claim 12, wherein the activation of T cells is
20 controlled by the release of cytokines and/or chemokines by the mature dendritic cells.

15. The artificial immune system of claim 13, wherein said cytokines and/or chemokines are selected from the group consisting of CCL-21 and CXCL13.

16. The artificial immune system of claim 14, wherein said cytokines and/or chemokines are selected from the group consisting of CCL-21 and CXCL13.

5 17. The artificial immune system of claim 13, wherein said cytokines and/or chemokines comprise CCL-21.

18. The artificial immune system of claim 14, wherein said cytokines and/or chemokines comprise CCL-21

10

19. The artificial immune system of claim 1, wherein said system further comprises stromal cells distributed in said matrix.

20. The artificial immune system of claim 19, wherein said stromal cells are BLS4
15 stromal cells.

21. The artificial immune system of claim 19, wherein said stromal cells are human stromal cells.

20 22. The artificial immune system of claim 19, wherein said stromal cells form a physical scaffold to support T cell and dendritic cell motility and interactions.

23. A method of evaluating the potential reaction of an animal to an agent, said method comprising:

administering an agent to the artificial immune system of claim 1; and

evaluating the B cell and/or T cell responses to said agent.

5

24. The method of claim 23, wherein said method further comprising administering one or more cytokines and/or chemokines to the artificial immune system.

25. The method of claim 24, wherein said cytokine is selected from the group

10 consisting of CCL21 and CXCL13.

26. The method of claim 24, wherein said cytokines comprise CCL21.

27. The method of claim 24, wherein said chemokine is selected from the group

15 consisting of CCL21 and CXCL13.

28. The method of claim 23, wherein said agent is selected from the group consisting of a vaccine, an adjuvant, an immunotherapy candidate, a cosmetic, a drug, a biologic, and a chemical compound.

20

29. The artificial immune system of claim 1, wherein said system comprises B cells and T cells distributed in said matrix, and said dendritic cells comprise both mature and

immature dendritic cells, the maturation state of the dendritic cells being controlled by the choice of culture media.

30. The artificial immune system of claim 1, wherein said system comprises B cells
5 and T cells distributed in said matrix, and said dendritic cells comprise both mature and immature dendritic cells, the maturation state of the dendritic cells being controlled by the choice of serum added to the culture media.

31. The artificial immune system of claim 1, wherein said system comprises B cells
10 and T cells distributed in said matrix, and said dendritic cells comprise both mature and immature dendritic cells, the maturation state of the dendritic cells being controlled by the addition of cytokines and/or chemokines to the culture media

32. The artificial immune system of claim 1, wherein said system comprises B cells
15 and T cells distributed in said matrix, and said dendritic cells comprise both mature and immature dendritic cells, the maturation state of the dendritic cells being controlled by the use of cells from a vaccination site.

20

Figure 1. The state of the DCs can dictate their migration behavior.




Figure 2. Mature DCs lead to T cell proliferation in a collagen layer.





Figure 3. Detection of OT-II reporter T cell responses.






Figure 4. A method to enhance the expansion of rare T cells *in vitro*: use of chemokine CCL21.




Figure 5. ECM production by BLS4 lymph node stromal cells.




Figure 6. Effects of BLS4 stromal cells on lymphocyte survival.




Figure 7. The ratio of immature to mature dendritic cells present in T-DC co-cultures impacts T cell proliferation and T cell survival.




Figure 8. BLS4 stromal cells form reticular networks in protein-conjugated inverse opal scaffolds.




Figure 9. Immature population of the RT-DCs from the VSM (membrane) or the VSC (cushion).

Before maturation

Before
Maturation




Figure 10. After maturation with *Candida albicans*/tetanus toxoid antigens and TNF α .

